Re AGN...
Allergan has maintained a privileged position in the drug industry with its eye care products and its Botox monopoly. It's good to be the king. Various organizations have praised AGN's management and gameplan, but are they really that good or is it just another case of "being born on third and thinking they hit a triple"?
Their eye care business is being cut into by ACL, and there is increasingly serious competition in the cosmetic wrinkle and implant business. Years of non competition have left AGN fat,lazy and arrogant. They are like the old telephone company, "We don't care, we don't have to care". Now they are facing real competition, my prediction is they are not going to fare too well.
ACL is making significant inroads into their core eye business. How significant??? Well Novartis is trying to buy ACL...That significant.
AGN is trying to cash in on the aesthetic medical field, and they are not doing that well. Botox is being sucessfully challenged by Dysport, who is outmarketing them. In the next year or so other competitors will enter the market.
J&J Mentor is kicking their a$$ in the breast implant business garnering over 60% of the business.
AGN has been pushing LaTisse, but there are several other products which do the same thing at a much lower price and are readily available without having to go to a doctor's office., eg RapidLash
":>) JL
PS Just yesterday I talked with a couple of medical researchers from HMS. They have what they consider a very exciting development in the immune-inflamatory system and had recently returned from a round discussing this with some of the major biotechs. One of them was was AGN. They were distinctly unimpressed with the research department there.
AI
Market Data 
Markets 
